Insmed (NASDAQ:INSM) Price Target Raised to $172.00

Insmed (NASDAQ:INSM) had its target price increased by Guggenheim from $125.00 to $172.00 in a research note published on Monday, MarketBeat Ratings reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. Stifel Nicolaus upped their target price on Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Wells Fargo & Company increased their price target on Insmed from $140.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 3rd. Morgan Stanley boosted their price objective on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Finally, Leerink Partners increased their target price on Insmed from $100.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 10th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $139.86.

Insmed Price Performance

Shares of NASDAQ INSM opened at $145.93 on Monday. Insmed has a twelve month low of $60.40 and a twelve month high of $149.08. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $30.85 billion, a price-to-earnings ratio of -25.56 and a beta of 0.97. The business has a 50 day simple moving average of $117.50 and a 200-day simple moving average of $90.98.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same quarter last year, the business earned ($1.94) earnings per share. The business’s revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Roger Adsett sold 25,000 shares of the stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the transaction, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. This represents a 19.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 24,272 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the sale, the insider owned 54,902 shares in the company, valued at $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 378,382 shares of company stock valued at $40,169,038. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Osaic Holdings Inc. raised its stake in shares of Insmed by 84.8% in the 2nd quarter. Osaic Holdings Inc. now owns 8,751 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 4,015 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Insmed by 0.8% during the second quarter. China Universal Asset Management Co. Ltd. now owns 36,582 shares of the biopharmaceutical company’s stock worth $3,682,000 after acquiring an additional 277 shares during the period. Orion Porfolio Solutions LLC grew its holdings in Insmed by 8.0% during the second quarter. Orion Porfolio Solutions LLC now owns 41,817 shares of the biopharmaceutical company’s stock worth $4,208,000 after acquiring an additional 3,082 shares during the period. Thrivent Financial for Lutherans bought a new stake in Insmed in the second quarter worth about $861,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Insmed in the 2nd quarter valued at about $291,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.